Literature DB >> 22431799

Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis.

Craig S Wong1, Jody C Mooney, John R Brandt, Amy O Staples, Srdjan Jelacic, Daniel R Boster, Sandra L Watkins, Phillip I Tarr.   

Abstract

BACKGROUND: Escherichia coli O157:H7 is the leading cause of hemolytic uremic syndrome (HUS). Risk factors for development of this complication warrant identification.
METHODS: We enrolled children infected with E. coli O157:H7 within 1 week of the onset of diarrhea in this prospective cohort study. The study was conducted in 5 states over 9.5 years . The primary and secondary outcomes were HUS (hematocrit <30% with smear evidence of hemolysis, platelet count <150 × 10(3)/µL, and serum creatinine concentration > upper limit of normal for age) and oligoanuric HUS. Univariate and multivariable and ordinal multinomial regression analyses were used to test associations between factors apparent during the first week of illness and outcomes.
RESULTS: Of the 259 children analyzed, 36 (14%) developed HUS. Univariate analysis demonstrated that children who received antibiotics during the diarrhea phase more frequently developed HUS than those who did not (36% vs 12%; P = .001). The higher rate of HUS was observed across all antibiotic classes used. In multivariable analysis, a higher leukocyte count (adjusted odds ratios [aOR] 1.10; 95% CI, 1.03-1.19), vomiting (aOR 3.05; 95% CI, 1.23-7.56), and exposure to antibiotics (aOR 3.62; 95% CI, 1.23-10.6) during the first week of onset of illness were each independently associated with development of HUS. Multinomial ordinal logistic regression confirmed that initial leukocyte count and antibiotic use were independently associated with HUS and, additionally, these variables were each associated with the development of oligoanuric HUS.
CONCLUSIONS: Antibiotic use during E. coli O157:H7 infections is associated with a higher rate of subsequent HUS and should be avoided.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22431799      PMCID: PMC3493180          DOI: 10.1093/cid/cis299

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  35 in total

1.  von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome.

Authors:  H M Tsai; W L Chandler; R Sarode; R Hoffman; S Jelacic; R L Habeeb; S L Watkins; C S Wong; G D Williams; P I Tarr
Journal:  Pediatr Res       Date:  2001-05       Impact factor: 3.756

2.  The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.

Authors:  C S Wong; S Jelacic; R L Habeeb; S L Watkins; P I Tarr
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

3.  The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients.

Authors:  S Dundas; W T Todd; A I Stewart; P S Murdoch; A K Chaudhuri; S J Hutchinson
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

4.  Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice.

Authors:  X Zhang; A D McDaniel; L E Wolf; G T Keusch; M K Waldor; D W Acheson
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

5.  Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome.

Authors:  Wayne L Chandler; Srdjan Jelacic; Daniel R Boster; Marcia A Ciol; Glyn D Williams; Sandra L Watkins; Takashi Igarashi; Phillip I Tarr
Journal:  N Engl J Med       Date:  2002-01-03       Impact factor: 91.245

6.  Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection.

Authors:  K Ikeda; O Ida; K Kimoto; T Takatorige; N Nakanishi; K Tatara
Journal:  Clin Nephrol       Date:  1999-12       Impact factor: 0.975

7.  Haemolytic uraemic syndrome: prognostic factors.

Authors:  D A Green; W G Murphy; W S Uttley
Journal:  Clin Lab Haematol       Date:  2000-02

8.  Escherichia coli O157:H7 infections: discordance between filterable fecal shiga toxin and disease outcome.

Authors:  Nancy A Cornick; Srdjan Jelacic; Marcia A Ciol; Phillip I Tarr
Journal:  J Infect Dis       Date:  2002-06-10       Impact factor: 5.226

9.  Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis.

Authors:  Nasia Safdar; Adnan Said; Ronald E Gangnon; Dennis G Maki
Journal:  JAMA       Date:  2002-08-28       Impact factor: 56.272

10.  Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response.

Authors:  P T Kimmitt; C R Harwood; M R Barer
Journal:  Emerg Infect Dis       Date:  2000 Sep-Oct       Impact factor: 6.883

View more
  76 in total

1.  Performance of Stool-testing Recommendations for Acute Gastroenteritis When Used to Identify Children With 9 Potential Bacterial Enteropathogens.

Authors:  Gillian A M Tarr; Linda Chui; Bonita E Lee; Xiao-Li Pang; Samina Ali; Alberto Nettel-Aguirre; Otto G Vanderkooi; Byron M Berenger; James Dickinson; Phillip I Tarr; Steven Drews; Judy MacDonald; Kelly Kim; Stephen B Freedman
Journal:  Clin Infect Dis       Date:  2019-09-13       Impact factor: 9.079

2.  Therapy: Azithromycin and decolonization after HUS.

Authors:  Michael E Seifert; Phillip I Tarr
Journal:  Nat Rev Nephrol       Date:  2012-05-01       Impact factor: 28.314

3.  Azithromycin decolonization of STEC--a new risk emerges.

Authors:  Michael E Seifert; Phillip I Tarr
Journal:  Nat Rev Nephrol       Date:  2012-06-05       Impact factor: 28.314

Review 4.  Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis.

Authors:  Stephen B Freedman; Jianling Xie; Madisen S Neufeld; William L Hamilton; Lisa Hartling; Phillip I Tarr; Alberto Nettel-Aguirre; Anderson Chuck; Bonita Lee; David Johnson; Gillian Currie; James Talbot; Jason Jiang; Jim Dickinson; Jim Kellner; Judy MacDonald; Larry Svenson; Linda Chui; Marie Louie; Martin Lavoie; Mohamed Eltorki; Otto Vanderkooi; Raymond Tellier; Samina Ali; Steven Drews; Tim Graham; Xiao-Li Pang
Journal:  Clin Infect Dis       Date:  2016-02-24       Impact factor: 9.079

5.  Management of suspected infectious diarrhoea by English GPs: are they right?

Authors:  Cliodna Am McNulty; Gemma Lasseter; Neville Q Verlander; Harry Yoxall; Philippa Moore; Sarah J O'Brien; Mark Evans
Journal:  Br J Gen Pract       Date:  2014-01       Impact factor: 5.386

6.  Identification of a wide range of motifs inhibitory to shiga toxin by affinity-driven screening of customized divalent peptides synthesized on a membrane.

Authors:  Mihoko Kato; Miho Watanabe-Takahashi; Eiko Shimizu; Kiyotaka Nishikawa
Journal:  Appl Environ Microbiol       Date:  2014-12-01       Impact factor: 4.792

Review 7.  Laboratory diagnosis of bacterial gastroenteritis.

Authors:  Romney M Humphries; Andrea J Linscott
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

8.  Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome.

Authors:  Alejandro Balestracci; Sandra Mariel Martin; Ismael Toledo; Caupolican Alvarado; Raquel Eva Wainsztein
Journal:  Pediatr Nephrol       Date:  2013-02-06       Impact factor: 3.714

Review 9.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 10.  Pathogenicity, host responses and implications for management of enterohemorrhagic Escherichia coli O157:H7 infection.

Authors:  Nathan K Ho; Aleah C Henry; Kathene Johnson-Henry; Philip M Sherman
Journal:  Can J Gastroenterol       Date:  2013       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.